These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cerebral and parotid metachronous metastases from an ovarian carcinoma. Canales Ugarte S; Cassinello Espinosa J Clin Transl Oncol; 2006 Nov; 8(11):839-40. PubMed ID: 17134977 [No Abstract] [Full Text] [Related]
3. [Ovarian mucinous carcinoma in a 12-year old girl]. Juszkiewicz P; Niedzielski A Ginekol Pol; 1993 Jun; 64(6):314-6. PubMed ID: 8397149 [TBL] [Abstract][Full Text] [Related]
4. The consequences of unsuspected secondary ovarian neoplasia: a clinical presentation of four case histories. Roley KM; Reza Hafez G; Buchler DA Gynecol Oncol; 1990 Feb; 36(2):277-80. PubMed ID: 2153625 [TBL] [Abstract][Full Text] [Related]
7. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage. Ljuca D; Fatusić Z; Iljazović E; Ahmetović B Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744 [TBL] [Abstract][Full Text] [Related]
8. Ovarian carcinoma of low malignant potential: staging and treatment. Nation JG; Krepart GV Am J Obstet Gynecol; 1986 Feb; 154(2):290-3. PubMed ID: 3004219 [TBL] [Abstract][Full Text] [Related]
9. Survival in women with ovarian cancer before and after the introduction of adjuvant paclitaxel; a 25-year, single institution review. Shireen R; Brennan D; Flannelly G; Fennelly D; Lenehan P; Foley M Ir Med J; 2012 Feb; 105(2):47-50. PubMed ID: 22455239 [TBL] [Abstract][Full Text] [Related]
14. Continuous Low-Dose Oral Cyclophosphamide and Methotrexate as Maintenance Therapy in Patients With Advanced Ovarian Carcinoma After Complete Clinical Response to Platinum and Paclitaxel Chemotherapy. El-Husseiny K; Motawei H; Ali MS Int J Gynecol Cancer; 2016 Mar; 26(3):437-42. PubMed ID: 26825824 [TBL] [Abstract][Full Text] [Related]
15. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Bamias A; Psaltopoulou T; Sotiropoulou M; Haidopoulos D; Lianos E; Bournakis E; Papadimitriou C; Rodolakis A; Vlahos G; Dimopoulos MA Cancer; 2010 Mar; 116(6):1462-8. PubMed ID: 20108307 [TBL] [Abstract][Full Text] [Related]
16. Feasibility study on biweekly paclitaxel treatment as maintenance chemotherapy in advanced müllerian carcinoma. Minagawa Y; Shimada M; Itamochi H; Sato S; Sato S; Okada M; Kitada F; Kigawa J Gynecol Obstet Invest; 2012; 73(4):272-6. PubMed ID: 22378216 [TBL] [Abstract][Full Text] [Related]
17. Role of neoadjuvant chemotherapy in the management of advanced ovarian cancer. Zhao D; Wu LY; Wang XB; Li XG Asian Pac J Cancer Prev; 2015; 16(6):2369-73. PubMed ID: 25824766 [TBL] [Abstract][Full Text] [Related]
18. Taxol (paclitaxel) safety in patients with platinum pretreated ovarian carcinoma: an interim analysis of a phase II multicenter study. Guastalla JP; Lhommé C; Dauplat J; Namer M; Bonneterre J; Oberling F; Pouillart P; Fumoleau P; Kerbrat P; Tubiana N Ann Oncol; 1994; 5 Suppl 6():S33-8. PubMed ID: 7865432 [TBL] [Abstract][Full Text] [Related]
19. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study. Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169 [TBL] [Abstract][Full Text] [Related]
20. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC). Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]